Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
30 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
TetraLogic Pharmaceuticals - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'TetraLogic Pharmaceuticals - Product Pipeline Review - 2014', provides an overview of the TetraLogic Pharmaceuticals's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of TetraLogic Pharmaceuticals's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of TetraLogic Pharmaceuticals including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of TetraLogic Pharmaceuticals's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the TetraLogic Pharmaceuticals's pipeline products Reasons to buy - Evaluate TetraLogic Pharmaceuticals's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of TetraLogic Pharmaceuticals in its therapy areas of focus - Identify new drug targets and therapeutic classes in the TetraLogic Pharmaceuticals's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of TetraLogic Pharmaceuticals and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of TetraLogic Pharmaceuticals - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of TetraLogic Pharmaceuticals and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 TetraLogic Pharmaceuticals Snapshot 4 TetraLogic Pharmaceuticals Overview 4 Key Information 4 Key Facts 4 TetraLogic Pharmaceuticals - Research and Development Overview 5 Key Therapeutic Areas 5 TetraLogic Pharmaceuticals - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 TetraLogic Pharmaceuticals - Pipeline Products Glance 10 TetraLogic Pharmaceuticals - Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Phase I Products/Combination Treatment Modalities 11 TetraLogic Pharmaceuticals - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 TetraLogic Pharmaceuticals - Drug Profiles 13 birinapant 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 SHP-141 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Small Molecules to Target Caspase and Inhibitor Of Apoptosis Protein for Cancer and Hepatitis B Virus Infection 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 TetraLogic Pharmaceuticals - Pipeline Analysis 19 TetraLogic Pharmaceuticals - Pipeline Products by Target 19 TetraLogic Pharmaceuticals - Pipeline Products by Route of Administration 20 TetraLogic Pharmaceuticals - Pipeline Products by Molecule Type 21 TetraLogic Pharmaceuticals - Pipeline Products by Mechanism of Action 22 TetraLogic Pharmaceuticals - Recent Pipeline Updates 23 TetraLogic Pharmaceuticals - Dormant Projects 27 TetraLogic Pharmaceuticals - Locations And Subsidiaries 28 Head Office 28 Appendix 29 Methodology 29 Coverage 29 Secondary Research 29 Primary Research 29 Expert Panel Validation 29 Contact Us 30 Disclaimer 30
List of Tables TetraLogic Pharmaceuticals, Key Information 4 TetraLogic Pharmaceuticals, Key Facts 4 TetraLogic Pharmaceuticals - Pipeline by Indication, 2014 7 TetraLogic Pharmaceuticals - Pipeline by Stage of Development, 2014 8 TetraLogic Pharmaceuticals - Monotherapy Products in Pipeline, 2014 9 TetraLogic Pharmaceuticals - Phase II, 2014 10 TetraLogic Pharmaceuticals - Phase I, 2014 11 TetraLogic Pharmaceuticals - Preclinical, 2014 12 TetraLogic Pharmaceuticals - Pipeline by Target, 2014 19 TetraLogic Pharmaceuticals - Pipeline by Route of Administration, 2014 20 TetraLogic Pharmaceuticals - Pipeline by Molecule Type, 2014 21 TetraLogic Pharmaceuticals - Pipeline Products by Mechanism of Action, 2014 22 TetraLogic Pharmaceuticals - Recent Pipeline Updates, 2014 23 TetraLogic Pharmaceuticals - Dormant Developmental Projects,2014 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.